Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...

A little over a year ago, I woke up in the middle of the night with an itchy scalp. I didn’t give it much thought, assuming ...

Hives are one of the most common skin conditions in the world. Even newborns and toddlers can be affected. The good news is ...

Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and ...

Results from a confirmatory study show that dupilumab significantly reduces itch in patients with uncontrolled chronic spontaneous urticaria.

Omalizumab biosimilar is under clinical development by Kashiv BioSciences and currently in Phase III for Chronic Urticaria Or Hives.

Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing ...

Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic ...

Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second ...

Sanofi has reported that Phase III LIBERTY-CUPID Study C of Dupixent in patients with chronic spontaneous urticaria met ...

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...